The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000587303
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
10/03/2026
Date registered
Help: Date registered
11/05/2026
Date last updated
Help: Date last updated
11/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
11/05/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
Using PET-CT imaging to explore new ways of identifying and monitoring endometriosis
Scientific title
REpurposing Positron Emission Tomography Imaging for the Diagnosis and Surveillance of Endometriosis: REPETE Human Pilot
Additional trial identifiers [1] 316700 0
Nil known
Universal Trial Number (UTN)
Trial acronym
REPETE Human Pilot
Related trial records

Health condition
Health condition(s) studied:
Endometriosis 340946 0
Condition category
Condition code
Public Health 337136 337136 0 0
Other public health
Reproductive Health and Childbirth 337137 337137 0 0
Other reproductive health and childbirth disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The intervention is a single dose of 1 MBq per kilogram of Fluoro-17beta-estradiol (FES) followed by a 10 minute dynamic PET/CT scan performed using the Siemens Biograph Vision Quadra PET/CT scanner.
The PET/CT scan will take place at Melbourne Theranostic Innovation Centre (MTIC). The scan will be done within approx. 3 months prior to surgery.
The single dose of FES will be administered intravenously via a cannula by the MTIC staff prior to the PET/CT scan.
Intervention code [1] 333376 0
Diagnosis / Prognosis
Description of the comparator or control
Following surgery, PET reports will be compared with the corresponding surgical and histology findings to evaluate how effectively PET imaging identifies endometriosis.
Control group
Active

Outcomes
Primary outcome [1] 344618 0
Sensitivity of Fluoro-17beta-estradiol (FES) in the detection of endometriosis.
Timepoint [1] 344618 0
The primary endpoint will be assessed after surgery and subsequent histological review (within 2 weeks of surgery).
Secondary outcome [1] 458637 0
Accuracy of FES for detection of endometriosis stage and distribution (composite outcome).
Timepoint [1] 458637 0
After surgery and subsequent histological review (within 2 weeks of surgery).
Secondary outcome [2] 458638 0
Comparison of FES to existing gold standard imaging for detection of endometriosis stage and distribution (composite outcome).
Timepoint [2] 458638 0
Standard imaging completed prior to enrolment. PET/CT within 3 months preceding surgery.
Secondary outcome [3] 458639 0
Sensitivity of FES in the detection of endometriosis in hormone users and non-users.
Timepoint [3] 458639 0
This assessment will occur after the baseline demographic and medical history questionnaires, PET/CT and surgery will be completed within approx. 4 to 5 months post enrolment.
Secondary outcome [4] 458640 0
Patient satisfaction with PET-CT protocol.
Timepoint [4] 458640 0
Participants need to submit the questionnaire within 4 weeks of their PET/CT scan.

Eligibility
Key inclusion criteria
Patients scheduled to undergo surgery for suspected endometriosis.
Aged between 18 – 45 years
Clinically suspected of having endometriosis, with pelvic imaging (high quality transvaginal U/S or MRI) suggestive of disease.
A prior surgery for endometriosis is not exclusionary, however, the participant must have imaging consistent with current disease in situ.
Planned for a laparoscopy (± hysterectomy) to treat endometriosis at Epworth.
Patients who are suppressing their menstrual cycle with hormone contraceptives are eligible (with capped recruitment in this group to a maximum of 8 participants).
Minimum age
18 Years
Maximum age
45 Years
Sex
Females
Healthy volunteers
No
Key exclusion criteria
Unwilling or unable to provide informed consent
Inability to comply with protocol
Contraindications to PET or CT including allergy to any of the protocol medications
Severe claustrophobia not amenable to medical management
Malignancy or suspected malignancy
History of radiation therapy or exposure to other high amounts of radiation
Premenarchal
Post-menopausal
Pregnant or trying to conceive during the study period
Breastfeeding

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
The study assigns the intervention to a single group (i.e., PET/CT scan). The PET/CT scan data is compared to the surgical/histological data obtained as standard of care for the same group of participants.
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 321305 0
Charities/Societies/Foundations
Name [1] 321305 0
Epworth Medical Foundation
Country [1] 321305 0
Australia
Primary sponsor type
Hospital
Name
Epworth HealthCare
Address
Country
Australia
Secondary sponsor category [1] 324058 0
None
Name [1] 324058 0
Address [1] 324058 0
Country [1] 324058 0
Other collaborator category [1] 283871 0
Other Collaborative groups
Name [1] 283871 0
Melbourne Theranostic Innovation Centre
Address [1] 283871 0
Country [1] 283871 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319837 0
St Vincent’s Hospital Human Research Ethics Committee
Ethics committee address [1] 319837 0
Ethics committee country [1] 319837 0
Australia
Date submitted for ethics approval [1] 319837 0
21/07/2025
Approval date [1] 319837 0
15/10/2025
Ethics approval number [1] 319837 0
203/25

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148570 0
Dr Lauren Hicks
Address 148570 0
Department of Gynaecology, Epworth Healthcare. 320 Victoria Parade, East Melbourne, 3002, VIC
Country 148570 0
Australia
Phone 148570 0
+61 399583658
Fax 148570 0
Email 148570 0
Contact person for public queries
Name 148571 0
Veronica Abruzzo
Address 148571 0
Julia Argyrou Endometriosis Centre, 185-187 Hoddle Street, Richmond, 3121, VIC
Country 148571 0
Australia
Phone 148571 0
+61 448169586
Fax 148571 0
Email 148571 0
Contact person for scientific queries
Name 148572 0
Lauren Hicks
Address 148572 0
Department of Gynaecology, Epworth Healthcare. 320 Victoria Parade, East Melbourne, 3002, VIC
Country 148572 0
Australia
Phone 148572 0
+61 399583658
Fax 148572 0
Email 148572 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Not applicable



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.